A case in which the Court determined that the Biologics Price Competition and Innovation Act of 2009 allows for commercial notice of a “biosimilar product” to be effective if given prior to approval by the Food and Drug Administration (FDA), but that the Act’s notice requirement is not enforceable with an injunction.